Voyager Therapeutics (VYGR) Current Deferred Revenue (2016 - 2025)
Voyager Therapeutics (VYGR) has disclosed Current Deferred Revenue for 11 consecutive years, with $1.6 million as the latest value for Q4 2025.
- Quarterly Current Deferred Revenue fell 93.48% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, down 93.48% year-over-year, with the annual reading at $1.6 million for FY2025, 93.48% down from the prior year.
- Current Deferred Revenue hit $1.6 million in Q4 2025 for Voyager Therapeutics, down from $10.6 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $87.0 million in Q2 2022 to a low of $1.6 million in Q4 2025.
- Historically, Current Deferred Revenue has averaged $35.3 million across 5 years, with a median of $32.8 million in 2021.
- Biggest five-year swings in Current Deferred Revenue: skyrocketed 1250.21% in 2022 and later crashed 93.48% in 2025.
- Year by year, Current Deferred Revenue stood at $33.9 million in 2021, then surged by 75.23% to $59.4 million in 2022, then dropped by 27.78% to $42.9 million in 2023, then plummeted by 43.11% to $24.4 million in 2024, then plummeted by 93.48% to $1.6 million in 2025.
- Business Quant data shows Current Deferred Revenue for VYGR at $1.6 million in Q4 2025, $10.6 million in Q3 2025, and $20.5 million in Q2 2025.